Melodiol Global Health (AU:ME1) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Melodiol Global Health reported a robust second quarter in 2024 with unaudited revenues of $4.8 million, marking a 9% increase from the previous quarter and a 31% year-over-year increase. The growth has been largely attributed to the success of Mernova, one of its core business units, which saw a 25% increase in purchase orders from Q1. The company is focused on continuing this momentum by concentrating on its profitable divisions and introducing new products to meet strong consumer demand.
For further insights into AU:ME1 stock, check out TipRanks’ Stock Analysis page.